| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
145,981,000 |
| Market
Cap: |
305.10(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.13 - $2.88 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat diseases. Co.'s key product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. Co. has multiple programs in various stages of preclinical development including RGLS5579 as a clinical candidate in its glioblastoma multiforme program, its preclinical programs targeting the Hepatitis B virus and Non-Alcoholic Steatohepatitis program.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
25,516 |
25,516 |
25,516 |
| Total Sell Value |
$0 |
$30,379 |
$30,379 |
$30,379 |
| Total People Sold |
0 |
3 |
3 |
3 |
| Total Sell Transactions |
0 |
3 |
3 |
3 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-09-10 |
4 |
AS |
$7.70 |
$15,399 |
D/D |
(2,000) |
6,065,600 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-09-10 |
4 |
AS |
$7.70 |
$15,399 |
D/D |
(2,000) |
6,964,600 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-09-05 |
4 |
AS |
$7.07 |
$16,974 |
D/D |
(2,400) |
6,067,600 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-09-05 |
4 |
AS |
$7.07 |
$16,974 |
D/D |
(2,400) |
6,966,600 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-09-04 |
4 |
AS |
$7.11 |
$42,656 |
D/D |
(6,000) |
6,070,000 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-09-04 |
4 |
AS |
$7.11 |
$42,656 |
D/D |
(6,000) |
6,969,000 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-09-03 |
4 |
AS |
$6.95 |
$11,471 |
D/D |
(1,650) |
6,076,000 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-09-03 |
4 |
AS |
$6.95 |
$11,471 |
D/D |
(1,650) |
6,975,000 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-08-29 |
4 |
AS |
$6.84 |
$10,254 |
D/D |
(1,500) |
6,976,650 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-08-29 |
4 |
AS |
$6.84 |
$10,254 |
D/D |
(1,500) |
6,077,650 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-08-28 |
4 |
AS |
$6.96 |
$13,921 |
D/D |
(2,000) |
6,978,150 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-08-28 |
4 |
AS |
$6.96 |
$13,921 |
D/D |
(2,000) |
6,079,150 |
|
- |
|
| Xanthopoulos Kleanthis G |
President & CEO |
• • – |
2014-08-28 |
4 |
AS |
$7.06 |
$24,754 |
D/D |
(3,505) |
0 |
|
- |
|
| Xanthopoulos Kleanthis G |
President & CEO |
• • – |
2014-08-28 |
4 |
OE |
$0.38 |
$1,332 |
D/D |
3,505 |
3,505 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-08-27 |
4 |
AS |
$7.21 |
$10,821 |
D/D |
(1,500) |
6,980,150 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-08-27 |
4 |
AS |
$7.21 |
$10,821 |
D/D |
(1,500) |
6,081,150 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-08-22 |
4 |
AS |
$6.75 |
$35,443 |
D/D |
(5,250) |
6,981,650 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-08-22 |
4 |
AS |
$6.75 |
$35,443 |
D/D |
(5,250) |
6,082,650 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-08-21 |
4 |
AS |
$6.89 |
$17,222 |
D/D |
(2,500) |
6,986,900 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-08-21 |
4 |
AS |
$6.89 |
$17,222 |
D/D |
(2,500) |
6,087,900 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-08-20 |
4 |
AS |
$7.14 |
$21,424 |
D/D |
(3,000) |
6,989,400 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-08-20 |
4 |
AS |
$7.14 |
$21,424 |
D/D |
(3,000) |
6,090,400 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-08-15 |
4 |
AS |
$6.98 |
$10,115 |
D/D |
(1,450) |
6,093,400 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-08-15 |
4 |
AS |
$6.98 |
$10,115 |
D/D |
(1,450) |
6,992,400 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-08-14 |
4 |
AS |
$7.04 |
$12,324 |
D/D |
(1,750) |
6,094,850 |
|
- |
|
306 Records found
|
|
Page 10 of 13 |
|
|
0.12 (5.43%) 
